Ensysce Biosciences Announces Completion Of Site Initiation Visit For PF614-201 Clinical Study
Portfolio Pulse from Benzinga Newsdesk
Ensysce Biosciences (NASDAQ:ENSC) has completed the Site Initiation Visit (SIV) for the PF614-201 study, a critical step towards Phase 3. The study aims to evaluate the time of onset for PF614, a chemically modified opioid product. The trial results are expected by the end of 2023.
September 26, 2023 | 12:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ensysce Biosciences has completed a key step in the clinical study of PF614-201, potentially bringing the product closer to Phase 3. This could have a positive impact on the company's stock in the short term.
The completion of the Site Initiation Visit for the PF614-201 study is a significant milestone in the drug's development process. This progress could increase investor confidence in Ensysce Biosciences, potentially leading to a short-term increase in the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100